New NPY2 Receptor Drug Boosts GLP-1 Weight Loss by 31% in Mice
Nisotirostide, a novel NPY2R agonist, synergizes with GLP-1 drugs to amplify weight loss and improve glucose control independently of fat reduction.
Summary
Researchers at Eli Lilly have developed nisotirostide, a selective activator of the NPY2 receptor — a gut-brain signaling pathway involved in appetite regulation. In mice, nisotirostide alone reduced body weight by up to 12%, but when combined with a GLP-1 receptor agonist (GLP-1 RA), weight loss surged to 31%, suggesting meaningful synergy. Notably, blood sugar improvements were seen independent of weight loss, hinting at a direct metabolic effect. A Phase 1 clinical trial in 65 participants showed nisotirostide added about 2.58 kg of additional weight reduction on top of dulaglutide (a GLP-1 RA), with once-weekly dosing. Gastrointestinal side effects like nausea were common but mild to moderate. This positions nisotirostide as a potential add-on therapy for people with type 2 diabetes already on GLP-1 drugs who need greater metabolic control.
Detailed Summary
Obesity and type 2 diabetes (T2D) remain two of the most consequential metabolic threats to healthspan and longevity. Even the best-in-class GLP-1 receptor agonists (GLP-1 RAs) leave many patients with inadequate weight loss or glycemic control, creating a clear need for complementary therapies. Nisotirostide (LY3457263), developed by Eli Lilly, targets the NPY2 receptor — a neuropeptide Y receptor highly expressed in gut enteroendocrine cells and the brain, involved in appetite suppression and energy homeostasis.
In preclinical studies using mouse models, nisotirostide potently and selectively activated NPY2R signaling in vitro. As monotherapy, it reduced body weight by up to 12%. When combined with a GLP-1 RA, weight loss reached up to 31%, demonstrating clear pharmacological synergism. Critically, improved glucose control was observed independently of weight reduction, suggesting nisotirostide has direct metabolic actions beyond simply reducing food intake.
The Phase 1 clinical trial (NCT04641312) enrolled 65 participants — healthy volunteers and individuals with T2D on dulaglutide (1.5 mg once weekly). Nisotirostide was given as a single subcutaneous dose ranging from 0.025 to 1 mg. Pharmacokinetic data supported a once-weekly dosing schedule. At 1 mg, nisotirostide as monotherapy reduced mean body weight by 0.75 kg versus placebo (not statistically significant), but when added to dulaglutide, produced up to 2.58 kg additional weight loss versus dulaglutide alone — a statistically significant result. Gastrointestinal adverse events, primarily nausea and vomiting, were dose-dependent and rated mild to moderate in severity.
For clinicians and longevity-minded readers, this research is significant because it maps a new neurohormonal target onto existing GLP-1 RA frameworks. The weight-independent glucose improvements could be particularly valuable for metabolic health optimization. Limitations include the small Phase 1 sample size, short duration, and reliance on single-dose data; longer trials are needed to assess sustained efficacy and safety.
Key Findings
- Nisotirostide combined with a GLP-1 agonist reduced body weight by up to 31% in mice, versus 12% as monotherapy.
- Glucose control improved independently of weight loss in mouse models, suggesting a direct metabolic mechanism.
- In humans, adding nisotirostide to dulaglutide produced 2.58 kg additional weight loss versus GLP-1 alone (p<0.05).
- Pharmacokinetics support a convenient once-weekly subcutaneous dosing regimen.
- Gastrointestinal side effects were dose-dependent and mild to moderate — consistent with the GLP-1 RA drug class.
Methodology
Preclinical work evaluated nisotirostide binding affinity, receptor selectivity, body weight, food intake, body composition, and glucose/insulin parameters in mouse models, alone and in combination with GLP-1 RA. The Phase 1 clinical trial (NCT04641312) was a single ascending dose study in 65 participants — healthy adults and people with T2D on dulaglutide — assessing safety, tolerability, pharmacokinetics, and pharmacodynamics via subcutaneous doses of 0.025–1 mg. This summary is based on the abstract only, as the full paper is not open access.
Study Limitations
This is a Phase 1 single-dose study with a small sample size (N=65), limiting conclusions about sustained efficacy or long-term tolerability. The most impressive weight-loss data (31%) comes from mouse models, which do not always translate to human magnitude of effect. Summary is based on the abstract only, so full methodological details, statistical analysis, and secondary endpoints cannot be fully evaluated.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: